HAE icon

Haemonetics

69.14 USD
-1.09
1.55%
At close May 13, 4:00 PM EDT
After hours
69.14
+0.00
0.00%
1 day
-1.55%
5 days
8.57%
1 month
16.36%
3 months
11.00%
6 months
-24.67%
Year to date
-11.81%
1 year
-28.14%
5 years
-29.04%
10 years
68.84%
 

About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Employees: 3,657

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

40% more repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 88

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

17% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 41

4.43% more ownership

Funds ownership: 108.19% [Q3] → 112.61% (+4.43%) [Q4]

2% more call options, than puts

Call options by funds: $42.5M | Put options by funds: $41.7M

1% more funds holding

Funds holding: 303 [Q3] → 305 (+2) [Q4]

1% less capital invested

Capital invested by funds: $4.45B [Q3] → $4.42B (-$31.7M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$84
21%
upside
Avg. target
$95
37%
upside
High target
$105
52%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Raymond James
Andrew Cooper
18% 1-year accuracy
4 / 22 met price target
52%upside
$105
Strong Buy
Reiterated
9 May 2025
Needham
Mike Matson
38% 1-year accuracy
42 / 112 met price target
21%upside
$84
Buy
Maintained
8 May 2025

Financial journalist opinion

Based on 8 articles about HAE published over the past 30 days

Positive
Zacks Investment Research
1 day ago
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Neutral
Seeking Alpha
3 days ago
Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q4 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Olga Guyette – Vice President-Investor Relations & Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Rohin Patel – JPMorgan Marie Thibault – BTIG Mike Matson – Needham & Company Andrew Cooper – Raymond James Joanne Wuensch – Citi Anthony Petrone – Mizuho Financial Group Michael Petusky – Barrington Research Craig Bijou – Bank of America Securities Operator Good day, and thank you for standing by. Welcome to the Q4 2025 Haemonetics Corporation Earnings Conference Call.
Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript
Positive
Zacks Investment Research
4 days ago
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
Positive
Zacks Investment Research
5 days ago
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.90 per share a year ago.
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Neutral
PRNewsWire
6 days ago
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website
Financial release accessible online BOSTON , May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website
Positive
Zacks Investment Research
6 days ago
Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics
Positive
Zacks Investment Research
1 week ago
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
Positive
Zacks Investment Research
1 week ago
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
Neutral
PRNewsWire
1 month ago
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025
BOSTON , March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025.
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025
Positive
Zacks Investment Research
1 month ago
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Charts implemented using Lightweight Charts™